Want to see HCM full AI Analyst Report?
HCM Stock Chart & Stats
$15.74
$0.15(1.02%)
At close: 4:00 PM EST
$15.74
$0.15(1.02%)
Day’s Range― - ―
52-Week Range$9.77 - $19.50
Previous CloseN/A
Volume23.53K
Average Volume (3M)48.41K
Market Cap
$1.94B
Enterprise Value$1.29K
Total Cash (Recent Filing)$1.37B
Total Debt (Recent Filing)$97.89M
Price to Earnings (P/E)4.1
Beta0.38
Next Earnings
Jul 30, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.71
Shares Outstanding174,467,030
10 Day Avg. Volume34,563
30 Day Avg. Volume48,412
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.85
Price to Sales (P/S)4.16
P/FCF Ratio-28.96
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.30Price Target Upside-2.80% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.21
Revenue Forecast (FY)$614.44M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity (~0.08) and high balance-sheet score provide durable financial flexibility. This reduces interest burden and preserves capacity to fund R&D, withstand clinical setbacks, pursue partnerships or milestones, and avoid forced financing in downcycles.
Reasonable Gross MarginsSustaining ~38.7% gross margin indicates product economics that can support future profitability once revenue growth stabilizes. Healthy margins provide a structural buffer to absorb fixed R&D and SG&A spending and improve operating leverage as sales recover.
Diversified Commercial & Collaboration Revenue MixA business model combining direct product sales and collaboration/licensing revenue creates multiple durable cash levers: recurring product revenues plus milestone/royalty streams from partners. This diversification reduces single-source dependency and supports long-term funding of pipeline programs.
Bears Say
Revenue Decline And Choppy GrowthA measurable revenue decline and volatile growth history signal weaker commercial traction and unpredictable top-line scaling. Over the medium term this undermines the company's ability to invest steadily in R&D, forecast cash needs, and demonstrate consistent market adoption of its therapies.
Negative Operating And Free Cash FlowSubstantial cash burn with negative operating and free cash flow reduces internal funding for development and commercialization. Persisting deficits increase reliance on external financing or milestone payments, raising dilution or execution risk and limiting strategic optionality over months.
Weak Earnings Quality; Net Income Driven By Non-operating ItemsNet income inflated by non-operating items makes reported profitability less repeatable and obscures operational health. For durable assessment, reliance on one-off gains reduces predictability of earnings, complicates reinvestment planning, and weakens the signal of genuine operating leverage.
HUTCHMED News
HCM FAQ
What was HUTCHMED’s price range in the past 12 months?
HUTCHMED lowest stock price was $9.77 and its highest was $19.50 in the past 12 months.
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $1.94B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Mar 05, 2026. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $2.5 by -$2.49.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Overvalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 0.15.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $0.01 in its last earnings report, missing expectations of $2.5. Following the earnings report the stock price went up 1.502%.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in HCM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HUTCHMED Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.30 (-2.80% Downside)
$15.30 (-2.80% Downside)
Hedge Fund Trend
Decreased
By 110.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
37.59%
Trailing 12-Months
Company Description
HUTCHMED
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
HCM Stock 12 Month Forecast
Average Price Target
$15.30
▼(-2.80% Downside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Alvotech
―
Ownership Overview
―
Insiders
0.09% Mutual Funds
0.09% Other Institutional Investors
99.75% Public Companies and
Individual Investors